Developmental of 6 Cancer Risk Assessment Questionnaire; CRAQ-6 (Thai Version)
Article Sidebar
Main Article Content
Abstract
OBJECTIVES: This medical study is to create a user-friendly and comprehensible Thai version questionnaire for the risk-based assessment of six primary cancers in Thailand. The questionnaire is designed to be easily administered as a self-test or interpreted by individuals proficient in the Thai language. The overarching aim is to enhance non-instrumental cancer screening within non-hospital-based settings, encouraging individuals identified as having cancer risk to seek early screening at hospitals. This proactive approach aims to conduct risk assessments, mitigating the risk of delayed cancer diagnoses and promoting preventive measures before the onset of symptoms.
MATERIALS AND METHODS: The methodology employed in this medical study involved a systematic review of the latest updated clinical practice guidelines from international entities, including NCCN, Standard textbooks. This comprehensive review was conducted in collaboration with the Thailand National Cancer Institute and relevant departments of the Thailand Royal College of Surgeons. Subsequently, a prototype questionnaire in Thai was developed. Expert consultation was sought from individuals associated as the Index of item-Objective Congruence (IOC) who specialize in each specific cancer and possess a minimum of five years of experience in the respective field; this involved engaging five experts per cancer risk assessment questionnaire. The refined questionnaire underwent linguistic refinement by consulting with linguists. Finally, the comprehensibility and effectiveness of the questionnaire were assessed through discussions with classified volunteers.
RESULTS: The self-evaluation Cancer Risk Assessment Questionnaire, acronymically known as CRAQ-6 from “Crack” and “Sick,” was successfully developed through standard scientific tool development. It exhibited high understandability across all educational levels among volunteers, although certain sections required additional reading for optimal comprehension.
CONCLUSION: In conclusion, the CRAQ-6 Questionnaire, developed using rigorous scientific tools for Thai contexts, demonstrates overall understandability across diverse educational levels. However, specific sections may require assistance from another reader for optimal comprehension. Ongoing refinement is essential to ensure its effectiveness in diverse research and clinical contexts.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hospital-based cancer registry, 2020. Bangkok; 2021. (Accessed February 6, 2024, at http://www.nci.go.th.)
Sarma EA, Walter FM, Kobrin SC. Achieving diagnostic excellence for cancer: symptom detection as a partner to screening. JAMA 2022;328(6):525-6. doi: 10.1001/ jama.2022.11744.
Department of medical services, ministry of public health. In: Im-Samran W, editor. Thailand medical services profile 2011 2014: first edition. Nonthaburi, Thailand. 2014. (Accessed February 6, 2024, at https://www.hiso.or.th/hiso/picture/re portHealth/report/report8.pdf)
Department of Health Dashboard. Screening rate of breast cancer among women 30-70 year-old by area [Internet]. Ministry of Public Health, Thailand. 2023. (Accessed February 6, 2024, at https://dashboard.anamai.moph.go.th/dashboard/ cancer3070?year=2023.).
Ministry of Public Health. Percentage of women undergoing cervical cancer screening [Internet]. Health KPI 2023. (Ac cessed February 6, 2024, at http://healthkpi.moph.go.th/kpi2/ kpi/index/?id=2020&kpi_year=2566&month=01&month=0 2&month=08&month=12&month=01&month=02&month= 03&month=07&month=09&month=12&month=12.)
National comprehensive cancer network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 2.2022 — March 9, 2022.
National comprehensive cancer network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer risk reduction. Version 1.2022 — January 31, 2022.
National comprehensive cancer network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Version 1.2022 — June 2, 2022.
The Royal College of Radiologists of Thailand. Guidelines for breast cancer screening, 2nd edition. Bangkok: The Royal College of Radiologists of Thailand; 2020.
The Royal College of Surgeons of Thailand. Clinical practice guidelines in surgery: general surgery: breast mass. CPG-S code: 8G98. (Accessed February 6, 2024, at https://www.rcst. or.th/en/clinical-practice-guidelines/).
National Cancer Institute, Department of Medical Services, Ministry of Public Health. Recommendations for appropriate breast cancer screening for Thailand. ISBN 978-974-442-885-7.
Parmigiani G, Berry D, Aguilar O, et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62(1):145-58. doi: 10.1086/301670.
The Royal College of Physicians of Thailand. Recommendations for the diagnosis and treatment of liver cancer in Thailand 2021 (Revised Edition) April 8, 2021.
National Cancer Institute, Department of Medical Services, Ministry of Public Health. Guidelines for the screening, diagnosis, and treatment of liver and bile duct cancer, 2nd edition. Bangkok: Academic Support Group, National Cancer Institute; 2001. ISBN 978-616-11-0634-8. 13. Liver Disease Association of Thailand. Thailand Guideline for Management of Hepatocellular Carcinoma 2021. Endorsed by The Royal College of Physicians of Thailand; 2021. 14. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-54. doi: 10.1055/s-2005-871194.
Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52 (Suppl 3):iii1-8. doi: 10.1136/gut.52.suppl_3.iii1.
National comprehensive cancer network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines®): lung cancer screening. Version 2.2022. July 19, 2022.
Jonas DE, Reuland DS, Reddy SM, et al. Screening for lung cancer with low-dose computed tomography: an evidence review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 198. AHRQ Publication No. 20-05266-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2021.
US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer. JAMA 2021 Mar 9;325(10): 962-70. doi:10.1001/jama.2021.1117.
National Cancer Institute. Guidelines for the diagnosis and treatment of lung cancer, 2nd edition. Department of Medical Services. first printing. Bangkok: National Cancer Institute, Department of Medical Services, Ministry of Public Health; Year of printing. ISBN 978-974-422-788-1.
Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012;176(7):573-85. doi: 10.1093/aje/kws151.
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123(1 Suppl):21S-49S. doi: 10.1378/chest.123.1_ suppl.21s.
Berek JS, Berek DL. Berek & Novak’s Gynecology. 16th ed. Stanford (CA): Wolters Kluwer; 2020.
Hanprasertpong J. Cervical Cancer. 1st ed. Sahamit Phatthanakan; 2018. ISBN 978-616-468-289-4.
National Cancer Institute. Guidelines for screening, diagnosis, and treatment of cervical cancer. First printing. Department of Medical Services, Ministry of Public Health; 2018. ISBN 978-974-422-842-6.
National Comprehensive Cancer Network (NCCN). NCCN Guideline for patients: colorectal cancer screening, Version 2.2021 – April 13, 2021.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): genetic/familial high-risk assessment: colorectal, Version 1.2022 — June 8, 2022.
National Cancer Institute. Guidelines for screening, diagnosis, and treatment of colorectal cancer. First revision. Bangkok: Sahamit Phatthanakan; 2015. ISBN 978-616-11-2486-1.
The Royal College of Surgeons of Thailand. Clinical practice guidelines in surgery: colorectal and anal surgery: colorectal and anal cancer. CPG-S code: 27C00.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer early detection, Version 1.2022 — February 16, 2022.
Wein AJ, Kavoussi LR, Partin AW, et al. Chapter 148: Epidemiology, Etiology, and Prevention of Prostate Cancer. Campbell-Walsh-Wein Urology, 12th edition. Canada: Elsevier; 2020. ISBN: 978-0-323-54642-3.
The Royal College of Surgeons of Thailand. Clinical practice guidelines in surgery: urology: prostate cancer. CPG-S code: 32U98.
National Cancer Institute, Department of Medical Services, Ministry of Public Health. Guidelines for screening, diagnosis, and treatment of prostate cancer. First printing. Bangkok: Department of Medical Services Publishing; 2017. ISBN 978-974-422-848-2. 33.Prostate cancer awareness for patient by expert group (PARANG). Risk factors causing prostate cancer. [Online] (Accessed February 6, 2024, at https://thaiprostatecancer.com/ risk-factors-causing-prostate-cancer/).
Hjelmborg J, PDQ Cancer Genetics Editorial Board, Zeegers M, et al. Prostate cancer: risk factors. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier; 2016. p. Table 148.2.
Hunxharek E, Ordonez-Mena JM, et al. Prostate cancer: risk factors. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia: Elsevier; 2016.
National Comprehensive Cancer Network. Prostate Cancer Early Detection (Version 1.2022). [Internet]. 2022. (Accessed February 6, 2024, at https://www.nccn.org/professionals/ physician_gls/pdf/prostate_detection.pdf).